

सं. / No. 50014/03/2020-CDN

भारत सरकार / Government of India

रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers

औषध विभाग / Department of Pharmaceuticals

\*\*\*\*\*

शास्त्री भवन, नई दिल्ली / Shastri Bhawan, New Delhi

Dated: 15<sup>th</sup> February, 2023

**Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of January, 2023-reg.**

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of January, 2023 for information.



15-02-2023  
(Shamim Uddin Ansari)

Under Secretary to the Govt. of India

Tel. 011-23387920

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr. PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers  
Department of Pharmaceuticals**

**1. Important policy decisions taken and major achievements during the month of January 2023:**

**A. National Pharmaceutical Pricing Authority (NPPA):**

**(i) Achievements:**

- (a) Retail prices of 48 new drugs have been fixed during the month of January, 2023 bringing cumulative figure to 2182 till January, 2023.
- (b) Ceiling price of 225 scheduled formulations have been fixed during the month of January, 2023 bringing cumulative figure to 344 till January, 2023.
- (c) On the basis of Monitoring & Enforcement activities, 240 Preliminary Notices (PN) and 03 Show Cause Notices (SCN) were issued.
- (d) E-news letter of NPPA for the month of December 2022 was published.
- (e) NPPA through Price Monitoring and Resource Units (PMRUs) in the States/ UTs have conducted five (5) market research analysis in January, 2023 to assess the availability of COVID Management Drugs in the States/ UTs.
- (f) An interactive webinar on the topic "PFMS: Release of Funds" was organised by NPPA on 19.01.2023 to provide the guidance to PMRUs regarding necessary pre-requisites and documentation to be submitted for release of funds. The PMRUs in the State/ UTs have actively participated in the webinar.

(ii) Total overcharged amount received during January, 2023 is Rs. 6.37 lacs.

(iii) One Review Order of La-Medica under Para 31 of DPCO 2013 has been issued.

**B. COVID Drug Management and Monitoring**

Data of export and import of COVID management drugs and their APIs was monitored and analysed with a view to ensuring appropriate policy response in case of any noticeable deviation from trend in drugs for COVID management.

**C. National Institutes of Pharmaceutical Education & Research (NIPERs):**

Major Achievements of NIPERs during the month are as under:

- (a) Out of 801 Research papers published during the current financial year, 94 papers have been published in the month of January, 2023
- (b) Out of 30 Patents filed during the current financial year, 9 patents filed in the month of January, 2023
- (c) Out of 26 MoU signed during the current financial year, 4 MoU has been signed in the month of January, 2023.
- (d) NIPER-Hajipur hosted the National Symposium on Strategies for Impediment of Emerging Infectious Diseases during January 10-11, 2023,
- (e) NIPER-Hajipur organised a Foundation Day address on cancer management in Bihar: present perspective and future directions.
- (f) NIPER Mohali organized 13<sup>th</sup> Convocation on 7<sup>th</sup> January, 2023.
- (g) NIPER Mohali organized ITEC Programme during January 09-20, 2023.

- (h) Soft Skills training programme was conducted at NIPER-Mohali during 9-14 January, 2023.
- (i) NIPER Mohali organized Webinar on “Humanized mouse model(s): more than a tour de force in translational biomedical research” on 11.01.2023.
- (j) NIPER Mohali organized General Safety Refresher Course (Chemical Safety).
- (k) The National Start-up Day 2023 celebrated at NIPER-Raebareli on 16 January, 2023.
- (l) NIPER-Raebareli celebrated the National Youth Day 2023 by organizing for Students Faculty and Staff on 12 January 2023.

**D. Schemes:**

**(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):**

Number of PMBJP Kendras functional		Sales under PMBJP at MRP Value in Rs. Crore and saving to common man during the month of January, 2023		Product basket (As on 31.01.2023)		Sale of Suvidha Sanitary Napkins @ Rs. 1/- per pad during the month January, 2023	Incentive provided in the month January, 2023
January 2023	Cumulative	Sale	Saving	Medicines	Surgical		
	(As on 31.01.2023)	In Rs. (Cr.)	In Rs. (Cr.) (Approx.)				
82	9082	122.13	733	1759	280	1.41 Cr.	8.75 Cr.

**(ii) Status of PLI Schemes:**

S. No.	Name of Scheme		Total No. of Application Received	No. of Applications approved in the month of January 2023	Total no. of applications approved till date
1.	Production Linked Incentive Scheme for Bulk Drug (Last EC Meeting held on 03.06.2022 on PLI Bulk Drugs)	Round 1	215	00	41
		Round 2	24	00	08
		Round 3	09	00	00
		Round 4	01	00	00
		Total	249	00	51 (1 Applicant has withdrawn)
2.	Production Linked Incentive	Round 1	28	0	13
		Round 2	14	0	08

	Scheme for Medical Device (Last EC Meeting held on 03.06.2022 on Medical Devices)	Round 3	18	0	00
		Total	60	0	21
3	Production Linked Incentive Scheme for Pharmaceuticals		278	N/A	55

(iii) The SSC for the scheme API-CF in its meeting held on 18.01.2023 approved 3 Projects for setting up CETP at Hyderabad, Telangana and Tindivanam, Tamil Nadu and anti-micro dial resistance Centre of excellence in Hyderabad, Telangana. The SSC has also accorded final approval to conduct 5 studies.

#### **E. International Cooperation:**

- (i) DoP participated in the 2<sup>nd</sup> Meeting of the Joint Working Group of Kingdom of Morocco and Republic of India on Medical Cooperation held on 12.01.2023 virtually, wherein inter alia, potential areas to strengthen bilateral cooperation in pharmaceuticals was discussed
- (ii) A Meeting was convened under the Chair of Secretary, Pharmaceuticals with Council of Scientific & Industrial Research (CSIR) on 12.01.2023 to explore cooperation with CSIR in technology transfer in international engagements. It was mutually agreed that CSIR would provide an appropriate mechanism to facilitate production and transfer of technology on a case-by-case basis in bilateral cooperation.
- (iii) An interaction with the World Health Organization (WHO) was organized on 13.01.2023 to understand trends in supply of donor funds to vaccines, therapeutics and diagnostics and the underlying factors. It was felt that necessary emphasis and funds need to be placed for incentivizing drug development, in addition to the current practice of funding established solutions largely through procurements. Other issues including taking the agenda of strengthening cooperation in pharmaceuticals in the Indian Presidency of G20, technical expertise to NIPERs and strengthening drug regulation in the country were also discussed.
- (iv) G20 1<sup>st</sup> Health Working Group Meeting was held during 18-20<sup>th</sup> January, 2023 at Thiruvananthapuram, Kerala. The side event inter alia included an optional visit to Jan Aushadhi Kendra near KIMS hospital. Delegates appreciated the importance of the intervention in improving access of affordable medical countermeasures.
- (v) The 1<sup>st</sup> meeting of the Inter-Ministerial High-Level Committee on Overseas Direct Investments in Pharmaceuticals was held on 27.01.2023 under the Chair of CEO, NITI Aayog to deliberate and foster an integrated and cohesive approach, on the global movement towards decentralized drug and vaccine manufacturing, in order to de-risk the supply chains. It was agreed that while the interest of African countries in incentivizing Indian pharma investments may be elicited to assess the favourable options, the appetite of Indian pharma investors may also be gauged. Further, MEA may also explore possibility of a political dialogue with the African Union to take forward dialogue in this regard.

**F. FDI inflow approved during this month: Rs. 1477 crore.**

**2. Important policy matters held up on account of prolonged inter-ministerial consultations:**

NIL

**3. No. of cases of 'sanction for prosecution' pending for more than three months:**

NIL

**4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:**

NIL

**5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):**  
Data on the SCDPM Portal for the month of January, 2023 has been updated by uploading the information from various Sections of this Department in the 2.0 version of the SCDPM Portal.

**6. Status of Rationalization of Autonomous Bodies:**

Completed

**7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:**

NIL

**8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:**

**(i) Department of Pharmaceuticals:**

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	Director/DS	06	05	01	A
2	Under Secretary	10	09	01	A
3	Principal Secretary Private	02	0	02	A
4	Section Officer	16	03	13	B
	<b>Total</b>	<b>34</b>	<b>17</b>	<b>17</b>	

**(ii) Public Sector Undertakings:**

**(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):**

S. No.	Designation	Vacant Positions
1	Senior Manager	05
2	Deputy General Manager	03
3	General Manager	06
	<b>Total</b>	<b>14</b>

**(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):**

S.No.	Designation	Vacant Positions
1	CGM	3
2	GM	3
3	DGM	12
4	Manager	20
	<b>Total</b>	<b>38</b>

**(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL)(under strategic sale):**

S.No.	Designation	Vacant Positions
1	DGM/AGM	3
2	Sr. Manager	3
3	DGM (Marketing)	1
4	DGM(Finance)	1
5	HoD (QA/QC)	1
	<b>Total</b>	<b>9</b>

**(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL**

**(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL**

**9. List of cases in which ACC directions have not been complied with:**  
NIL

**10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:**

(i) Pending at beginning of the month : (5)  
(ii) Received during the month : (0)  
(iii) Disposed of during the month : (2)  
(iv) Pending at end of the month : (3)

\*\*\*\*\*